Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 3, 1997, Pages 273-276

  Bellmunt, J ^a   Eres, N ^a   Ribas, A ^a   Casado, S ^a   Albanell, J ^a   Baselga, J ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Bladder cancer; Breast carcinoma; Continuous infusion; Ifosfamide; Sarcoma

Indexed keywords

IFOSFAMIDE; MESNA;

ADULT; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; BREAST CARCINOMA; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; MALE; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; THROMBOCYTOPENIA; VOMITING;

EID: 0030957056     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050658     Document Type: Article

References (27)

1. Antman KH (1992) Chemotherapy of advanced sarcomas of bone and soft tissue. Semin Oncol 19: 13-22
2. Antman KH, Montella D, Rosembaum C, Schwen M (1985) Phase II trial of ifosfamide with mesna in previously treated metastatic sarcoma. Cancer Treat Rep 69: 499-504
3. Bellmunt J, Morales S, Navarro M, Sole LA (1990) Ifosfamide + mitoxantrone in advanced breast cancer previously treated with anthracyclines. Cancer Chemother Pharmacol [Suppl] 26: S71-S73
4. Benjamin RS, Legha SS, Patel SR (1993) Single-agent ifosfamide studies in sarcomas of soft-tissue and bone: the M. D. Anderson experience. Cancer Chemother Pharmacol 31 [Suppl 2]: S174-S179
5. Brock N, Pohl J (1987) The basis of modern ifosfamide therapy. In: Brade WP, Nagel GA, Seeber S (eds) Contributions to oncology, vol 26. Karger, Munich, pp 1-11
6. Burkert H (1982) Ifosfamide: European perspective. Semin Oncol 9: 28-35
7. Czownicki Z, Utracka-Hutka B (1980) Clinical studies with uromitexan - an antidote against urotoxicity of haloxan. Preliminary results. Nowotory 30: 337-383
8. Delaflor-Weiss E, Uziely B, Muggia FM (1993) Protracted drug infusions in cancer treatment: an appraisal of 5-fluorouracil, doxorubicin, and platinums. Ann Oncol 4: 723-733
9. Elias AD, Eder JP, Shea T, Begg CB, Frei E, Antman KH (1990) High-dose ifosfamide with mesna uroprotection: a phase I study. J Clin Oncol 8: 170-178
10. Falkson G, Falkson HC (1976) Further experience with ifosfamide. Cancer Treat Rep 60: 955-957
11. Goldin A (1982) Ifosfamide in experimental tumor systems. Semin Oncol 9: 14-23
12. Goren PM, Wright RK, Pratt CB, Pell FE (1986) Dechloroethylation of ifosfamide and neurotoxicity. Lancet 11: 1219-1220
13. Hartley JM, Hansen L, Harland SJ, Nicholson PW, Pasini F, Souhami RL (1994) Metabolism of ifosfamide during a 3 day infusion. Br J Cancer 69: 931-936
14. Hortobagyi GN (1992) Activity of ifosfamide in breast cancer. Semin Oncol 19: 36-42
15. Kandylis K, Vassilomanolakis M, Tsoussis S, Efremidis AP (1989) Ifosfamide cardiotoxicity in humans. Cancer Chemother Pharmacol 24: 395-396
16. Le Cesne A, Antoine E, Spielmann M, Le Chevalier T, Brain E, Toussaint C, Janin N, Kayitalire L, Fontaine F, Genin J, Vanel D, Contesso G, Tursz T (1995) High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 13: 1600-1608
17. Lewis LD, Fitzgerald DL, Harper PG, Rogers HJ (1990) Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism. Br J Clin Pharmacol 30: 725-732
18. Loehrer PJ, Laurer R, Roth BJ, Williams SD, Kalasinski L, Einhorn LH (1988) Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 109: 540-546
19. Magrath IT, Sandlund JT, Rayer A, Rosemberg SA, Arasi V, Miser JS (1985) Treatment of recurrent sarcomas with ifosfamide (IF) (abstract 528). Proc Am Soc Clin Oncol 4: 136
20. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
21. Motzer RJ, Geller NL, Tan CY, Herr H, Morse N, Fair W (1991) Salvage chemotherapy for patients with germ cell tumor; the Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 67: 1305-1320
22. Palumbo R, Toma S, Comadone A, Oliva C, Vicenti M, Bumma C, Rosso R (1995) Ambulatory 4-day continuous-infusion schedule of high dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study. Ann Oncol 6: 193-196
23. Rodriguez V (1977) Efficacy of ifosfamide in patients with leukemia and lymphoma refractory to prior chemotherapy. In: Burket H, Voigt HC (eds) Proceedings of the international holoxan symposium, March 21-23, Asta-Werke AG, Düsseldorf, Germany, pp 160-162
24. Rosen G, Forscher C, Lowenbraun S, Eilber F, Eckardt J, Holmes C, Fu YS (1994) Synovial sarcoma: uniform response of metastases to high dose ifosfamide. Cancer 73: 2506-2511
25. Schimdt H, Kaufmann M, Grischke EM (1990) Ifosfamide combination chemotherapy in advanced breast cancer. Cancer Chemother Pharmacol [Suppl] 26: S81-S84
26. Sutton GP, Blessing JA, Manetta A, Homesley H, McGuire W (1992) Gynecologic Oncology Group studies with ifosfamide. Semin Oncol 19: 31-34
27. Witte R, Loehrer P, Dreicer R, Williams S, Elson P (1993) Ifosfamide in advanced urothelial carcinoma: an ECOG trial (abstract 707). Proc Am Soc Clin Oncol 12: 230